Comparative Pharmacology
Head-to-head clinical analysis: AVALIDE versus LOPRESSOR HCT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AVALIDE versus LOPRESSOR HCT.
AVALIDE vs LOPRESSOR HCT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Avalide is a combination of an angiotensin II receptor blocker (irbesartan) and a thiazide diuretic (hydrochlorothiazide). Irbesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively antagonizing the AT1 receptor. Hydrochlorothiazide increases sodium and water excretion by inhibiting the Na+/Cl- symporter in the distal convoluted tubule.
LOPRESSOR HCT is a combination of metoprolol tartrate (a beta-1 selective adrenergic receptor blocker) and hydrochlorothiazide (a thiazide diuretic). Metoprolol reduces heart rate, myocardial contractility, and blood pressure by blocking beta-1 receptors in the heart. Hydrochlorothiazide increases sodium and water excretion by inhibiting the Na+/Cl- symporter in the distal convoluted tubule of the kidney, reducing plasma volume.
AVALIDE (irbesartan/hydrochlorothiazide) is available as tablets containing 150/12.5 mg, 300/12.5 mg, or 300/25 mg. The typical starting dose is 150/12.5 mg once daily, titrated to 300/12.5 mg once daily as needed. Maximum dose is 300/25 mg once daily.
1-2 tablets (each containing metoprolol tartrate 50 mg and hydrochlorothiazide 25 mg) orally once daily, maximum 4 tablets daily.
None Documented
None Documented
Irbesartan: 11-15 h (terminal), HCTZ: 6-15 h (terminal). Clinical context: Steady state reached in 3-5 days; allows once-daily dosing.
Metoprolol: 3-7 hours (terminal half-life); extensive metabolizers (CYP2D6) ~3-4 h, poor metabolizers ~7-8 h. Hydrochlorothiazide: 6-15 hours (terminal half-life).
Renal: HCTZ ~70% unchanged; Irbesartan ~20% unchanged, remainder as metabolites via biliary (60%) and renal (20%). Combined: Renal ~50%, biliary/fecal ~50%.
Metoprolol: <5% unchanged in urine; rest metabolized in liver (CYP2D6) and excreted renally as metabolites. Hydrochlorothiazide: >95% excreted unchanged in urine within 24 hours via tubular secretion.
Category C
Category C
ARB and Thiazide Diuretic Combination
Beta-Blocker/Thiazide Diuretic Combination